NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Institut de Cancérologie de Lorraine
University of Nebraska
Eastern Cooperative Oncology Group
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Institut Paoli-Calmettes
National Cancer Institute (NCI)
Technical University of Munich
European Organisation for Research and Treatment of Cancer - EORTC